

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	APPLICATION NO. FILING DATE FIRST NAME		ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/006,014	12/04/2001	Chen Xing Su	10209.276	6898		
21999	7590 05/01/2003					
KIRTON AND MCCONKIE 1800 EAGLE GATE TOWER 60 EAST SOUTH TEMPLE P O BOX 45120 SALT LAKE CITY, UT 84145-0120			EXAMI	EXAMINER		
			OH, SIMON J			
			ART UNIT	PAPER NUMBER		
5.15.15.11.15	0111, 01 01110 0120		1615	ح		
			DATE MAILED: 05/01/2003			

Please find below and/or attached an Office communication concerning this application or proceeding.

		•	_	_					
,		Application	No.	Applicant(s)					
•		10/006,014		SU ET AL.					
	Office Action Summary	Examiner		Art Unit					
		Simon J. Oh		1615					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status									
1)[🛛	Responsive to communication(s) filed on 03 (October 2002							
2a)⊠	<u> </u>	nis action is no							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
· _	ion of Claims								
4)⊠	Claim(s) 1-10,12 and 13 is/are pending in the application.								
5 \	4a) Of the above claim(s) is/are withdrawn from consideration.								
·	5) Claim(s) is/are allowed.								
	6) Claim(s) <u>1-10,12 and 13</u> is/are rejected.								
·	Claim(s) is/are objected to.		•						
8) Claim(s) are subject to restriction and/or election requirement. Application Papers									
• •	The specification is objected to by the Examine	r ·			,				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.									
If approved, corrected drawings are required in reply to this Office action.									
12) The oath or declaration is objected to by the Examiner.									
Priority ι	ınder 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a)	☐ All b)☐ Some * c)☐ None of:								
	1. Certified copies of the priority documents	s have been re	eceived.						
	2. Certified copies of the priority documents	s have been re	eceived in Applicatio	n No	•				
* 5	 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
) The translation of the foreign language pro- Acknowledgment is made of a claim for domesti								
Attachmen		· •							
2) 🔲 Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	4) 5) 6)	Interview Summary (Notice of Informal Pa Other:	PTO-413) Paper No(atent Application (PT0					

Art Unit: 1615

DETAILED ACTION

Papers Received

Receipt is acknowledged of the applicant's amendment and response, both received on 03 October 2002.

Claim Rejections - 35 USC § 102

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The rejection of Claims 1 and 2 under 35 U.S.C. 102(b) as being anticipated by Moniz is hereby withdrawn.

Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The rejection of Claims 12 and 14 under 35 U.S.C. 103(a) has been rendered moot with the cancellation of those claims.

The rejection of Claims 1-10, 11, and 12 under 35 U.S.C. 103(a) as being unpatentable over Moniz in view of Nair *et al.*, and Wadsworth *et al.* is maintained.

Art Unit: 1615

Response to Arguments

The applicant's arguments, received on 03 October 2002, have been considered, but are not found to be persuasive.

The applicant's arguments against the references used in the rejection under 35 U.S.C. 103(a) essentially amount to a piecemeal analysis of the claims. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). The examiner finds sufficient motivation by one of ordinary skill in the art to combine the disclosures of Moniz and Nair *et al.*, as both references disclose pain relief and the use of fruit extracts as a pharmaceutical product.

With respect to the applicant's claims of treating pain through selective cyclooxygenase inhibition by limited dosing of *Morinda citrifolia*, the applicant still has not properly addressed the view of the examiner that such a method is inherent in the prior art. The breadth of the claims in their present form make no recitation of any specific dosage amounts, and as such, it is the view of the examiner that the prior art makes the instantly claimed invention obvious. In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., the combination of noni with a fruit extract to produce a food supplement) are not recited in the rejected claim(s).

Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). The applicant has not shown how the conceptualization of the instant application would

Art Unit: 1615

not have been within the purview of one of ordinary skill in the art at the time the instantly claimed invention was made. That if something is beneficial, then more of it is necessarily proportionately more beneficial is known as a fallacy in the art. Conversely, it is also known that if something is harmful, then less of it is not necessarily proportionately less harmful, and in fact, it may even be beneficial. The work of finding proper dosage amounts for any type of active ingredient is based in part upon these principles. As an anecdotal example, the benefits of vitamin A have been well established in the art. However, arctic explorers who have hunted and eaten polar bears have died, as polar bear livers contain vitamin A in such a great concentration that it is lethal to humans. It is the position of the examiner that the applicant has failed to show how the instantly claimed invention possesses a patentable novelty beyond these general principles.

The applicant's arguments appear to require a narrow interpretation of both the claims and the prior art. It is the position of the examiner that one of ordinary skill in the art, giving both the prior art and the claims in their present form their broadest reasonable interpretation, would find the claimed invention obvious in view of the prior art. See MPEP § 2111 and 2123. The rejection of the claims under 35 U.S.C. 103(a) is deemed proper and is maintained.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

Art Unit: 1615

MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

however, will the statutory period for reply expire later than SIX MONTHS from the mailing

date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Simon J. Oh whose telephone number is (703) 305-3265. The examiner can normally be reached on M-F 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703) 308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3014 for regular communications and (703) 305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

Simon J. Oh Examiner Art Unit 1615

sjo April 25, 2003

PHURMAN K. PAGE
SUPERVISORY PAYENT EXAMINER
TECHNOLOGY CENTER 1600

Page 5